Andrew Blauvelt MD, MBAPresident, Oregon Medical Research Center, Portland, Oregon
Andy Blauvelt is President of Oregon Medical Research Center in Portland, Oregon, a private dermatology clinical studies business. He received his undergraduate degree in Electrical Engineering at Purdue University, his medical degree at Michigan State University, and his Healthcare MBA from Portland State University/Oregon Health & Science University (OHSU). Dr. Blauvelt trained in dermatology at the University of Miami and in cellular immunology under the direction of Steve Katz at the National Institutes of Health (NIH). He has held senior staff tenured positions at the NIH, OHSU, and the Portland VA Medical Center. Andy’s clinical and research expertise is in immunology, psoriasis, atopic dermatitis, and biologic therapies for complex medical dermatology patients, having published over 300 papers and spoken across the world on these topics. Dr. Blauvelt is also an elected member of the American Society for Clinical Investigation (a leading society for physician-scientists), the International Psoriasis Council (the premier group of psoriasis experts in the world), and the International Eczema Council (the premier group of eczema experts in the world).
Dr. Blauvelt has served as a scientific adviser and/or clinical study investigator for AbbVie, Almirall, Arena, Athenex, Boehringer Ingelheim, Bristol-Myers Squibb, Dermavant, Eli Lilly and Company, Evommune, Forte, Galderma, Incyte, Janssen, Leo, Novartis, Pfizer, Rapt, Regeneron, Sanofi Genzyme, Sun Pharma, and UCB Pharma.
Recent Contributions to PracticeUpdate:
- Tralokinumab for Moderate to Severe Atopic Dermatitis
- Dupilumab Does Not Affect Correlates of Vaccine-Induced Immunity
- Secukinumab Is Superior to Ustekinumab in Clearing Moderate to Severe Plaque Psoriasis Up to 1 Year
- Ixekizumab in Moderate to Severe Plaque Psoriasis
- TNF-α Inhibitors Improve Insulin Sensitivity in Psoriasis Patients With Type 2 Diabetes